Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the mTOR signaling pathway
##plugins.themes.themeTen.article.main##
Keywords
pulmonary fibrosis, bleomycin, autophagy
Abstract
Objectives: Schisandrin B (Sch B) is an active monomer of Schisandrin, which has anti-fibrosis pharmacological action. We examined whether Sch B could also alleviates bleomycin-induced (BLM-Induced) pulmonary fibrosis in mice and explored its anti-fibrosis mechanism.
Methods: We evaluated the effect of Sch B on BLM-Induced pulmonary fibrosis in mice. Histopathological examination was performed by H&E staining and immunohistochemistry. The inflammatory cytokines including IL-6 and TNF-α in serum and alveolar lavage fluid were determined by ELISA. Biomarkers of oxidative stress in lung tissues were measured by corresponding kits. Western blotting and immunofluorescence were used to investigate whether Sch B could regulate autophagy through the mTOR signaling pathway, in order to explore the possible molecular mechanism of Sch B attenuating pulmonary fibrosis.
Results: The results indicated that Sch B could significantly attenuate inflammation and oxidative stress, and inhibit pulmonary fibrosis in mice lungs. In addition, Sch B promoted autophagy to attenuate pulmonary fibrosis. The anti-fibrosis effect of Sch B was accomplished through the mTOR signaling pathway.
Conclusions: The results suggest that the anti-fibrotic effect of Sch B may be related to the activation of autophagy through the mTOR signaling pathway. Sch B may be a potential agent for the treatment of IPF.
References
[2] Raghu G et al. An official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
[3] He Z, Xiu RZ, Jiao G, et al. Pharmacokinetics and tissue distribution study of schisandrin B in rats by ultra-fast liquid chromatography with tandem mass spectrometry[J].Journal of Pharmaceutical and Biomedical Analysisi,2013 (78- 79):136-140.
[4] Li WL, Xin HW, Xu AR, et al. In vivo effect of Schisandrin B on cytochrome P 450 enzyme activity[J].Phytomedicine,2013(20):760-765
[5] Ying Wang, Xiaoman Dong, Na Zhao, et al. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the wingless/integrase-1 signaling pathway. EXPERIMENTAL LUNG RESEARCH 2020, VOL. 46, NO. 6, 185–194
[6] Patel AS, Ling L, Alexander G, Jeffrey AH, Chang HA, Jiaofei C,Rosas IO, Morse D (2012) Autophagy in idiopathic pulmonary fibrosis. PLoS One 7(7):e41394
[7] D.M.Walters, S.R. Kleeberger, Mouse models of bleomycin-induced pulmonary fibrosis, Curr. Protoc. Pharmacol. 5 (46) (2008) 1–17.
[8] Moeller A, Ask K, Warburton D, Gauldie J, Kolb M: The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008, 40(3):362-382.
[9] Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of
pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41(4):467-470.
[10] In G.L., et al. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions. Respiratory Research, 2015. 16(1): p. 1-9
[11] Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S,Natsume T, Yanagawa T,Uwayama J, Warabi E, Yoshida H, Ishii T,Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E,Tanaka K. Homeostatic levels of p62 control cytoplasmic inclusion bodyformation in autophagy-deficient mice. Cell 131: 1149 –1163, 2007.
[12] M. I. Nasser, Shuoji Zhu, Chen Chen, et al. A Comprehensive Review on Schisandrin B and Its Biological Properties. Oxidative Medicine and Cellular Longevity
Volume 2020, Article ID 2172740, 13 pages
[13] Wang K et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy 2018; 14:269–282.
[14] Ferguson, K.T., E.E. Torr, K. Bernau, J. Leet, D. Sherris, and N.Sandbo. 2017. The novel mTOR complex 1/2 inhibitor P529 inhibits human lung myofibroblast differentiation. Journal of Cellular Biochemistry 118(8): 2241–2249.
[15] Bindu, S., V .B. Pillai, A. Kanwal, S. Samant, G.M. Mutlu, E. V erdin, N. Dulin, and M.P . Gupta. 2017. SIRT3 blocks myofibroblast differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage. American Journal of Physiology. Lung Cellular and Molecular Physiology 312 (1): L68–L78.
[16] Zhou, Li, Duan, Liu, Guan, Mei, et al. Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Mode. Inflammation 40:6, pages 2062-2073.
[17] Leask, A. 2010. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circulation Research 106 (11): 1675–1680.
[18] R. Vema, L. Kushwah, D. Gohel, M. Patel, T. Marvania, S. Balakrishnan, Evaluating the ameliorative potential of Quercetin against the bleomycin-induced pulmonary fibrosis in wistar rats, Pulm. Med. (2013) (Article ID 921724).
[19] M.A. Mouratis, V. Aidinis, Modeling pulmonary fibrosis with bleomycin, Curr. Opin. Pulm. Med. 17 (2011) 355–361.
[20] W. Liu, J. Wan, J.Z. Han, C. Li, D.D. Feng, S.J. Yue, et al., Antiflammin-1 attenuates
[21] P. Chitra, G. Saiprasad, R. Manikandan, G. Sudhandiran, Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-кB dependant TGF-ß activation: a biphasic experimental study, Toxicol. Lett. 219(2013)178–193
[22] Haspel JA, Choi AM (2011) Autophagy: a core cellular process with emerging links to pulmonary disease. Am J Respir Crit Care Med 184:1237–1246
[23] Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD (2009) Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 41:562–572
[24] Ashford TP, Porter KR (1962) Cytoplasmic components in hepatic cell lysosomes. J Cell Biol 12: 198–202.
[25] Araya J，Kojima J，Takasaka N，et al． Insufficient autophagy in idiopathic pulmonary fibrosis．Am J Physiol Lung Cell Mol Physiol,2013,304:56 -69．
[26] Ching JK, Weihl CC. Rapamycin-induced autophagy aggravates pathology and weakness in a mousemodel of VCP-associated myopathy. Autophagy. 2013; 9(5). Epub 2013/02/27. PMID: 23439279.
[27] Li X, Wu D, Shen J, Zhou M, Lu Y. Rapamycin induces autophagy in the melanoma cell line M14 via regulation of the expression levels of Bcl-2 and Bax. Oncology letters. 2013; 5(1):167–72. Epub 2012/12/21. PMID: 23255914; PubMed Central PMCID: PMCPMC3525347.
##plugins.themes.themeTen.article.sidebar##
##plugins.themes.themeTen.article.details##
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
